I期和IIA期非小细胞肺癌立体定向体部放疗与传统三维适形放疗后肺功能变化比较:TROG 09.02(CHISEL)3期试验分析
本研究分析CHISEL 3期试验中101例不可手术早期非小细胞肺癌患者的肺功能检查和6分钟步行试验,比较SBRT与CRT后的变化。线性回归模型显示,治疗后3个月和12个月两组在肺功能下降或6分钟步行距离上均无差异证据。尽管SBRT组靶区生物有效剂量显著更高,但两组呼吸功能下降无差异。
要点
- SBRT组靶区平均生物有效剂量125.92 Gy(SD 21.58)显著高于CRT组65.49 Gy(SD 6.32)。
- 治疗后3个月和12个月,两组肺功能下降及6分钟步行距离均无差异证据。
- CRT组计划靶区体积142.79 cc(SD 61.14)显著大于SBRT组46.15 cc(SD 23.39)。
核心结论
- 尽管SBRT组靶区生物有效剂量显著更高,两组在治疗后3个月和12个月观察到的呼吸功能下降无差异。
研究设计与样本
- 对TROG 09.02(CHISEL)3期试验中入组的101例不可手术早期非小细胞肺癌患者进行分析,其中33例接受CRT、61例接受SBRT、7例未接受治疗。
- 采用线性回归模型比较SBRT组与CRT组在治疗后3个月和12个月的肺功能检查参数及6分钟步行试验。
主要发现
- 原发肿瘤大小两组相似:SBRT组25 mm(SD 9),CRT组28 mm(SD 9)。
- CRT组计划靶区体积142.79 cc(SD 61.14)显著大于SBRT组46.15 cc(SD 23.39)。
- SBRT组靶区平均生物有效剂量125.92 Gy(SD 21.58)显著高于CRT组65.49 Gy(SD 6.32)。
- 肺减大体肿瘤体积并考虑运动后的平均剂量:CRT组8.9 Gy(SD 2.34),SBRT组4.37 Gy(SD 1.42)。
- 回归分析显示,治疗后3个月和12个月两组在肺功能下降或6分钟步行试验步行距离上均无差异证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The TROG 09.02 CHISEL trial compared conventional radiation therapy (CRT) with stereotactic body radiation therapy (SBRT) in patients with inoperable early-stage non-small cell lung cancer. Patients randomized to SBRT had less local failure and improved overall survival. This analysis reports differences in pulmonary function tests (PFTs) and the 6-minute walk test (SMWT) between patients who received SBRT and those who received CRT. METHODS AND MATERIALS: We analyzed the PFTs and SMWTs of all patients recruited to the CHISEL [trial. During this trial, patients underwent serial PFTs. Linear regression models were used to compare parameters between SBRT and CRT at 3 and 12 months after treatment. RESULTS: One hundred and one patients were enrolled; 33 patients were treated with CRT, 61 were treated with SBRT, and 7 did not receive treatment. Primary tumor size was similar between arms: SBRT 25 mm (standard deviation [SD], 9) and CRT 28 mm (SD, 9). On regression analysis, at 3 and 12 months, there was no evidence of a difference between arms in PFT decline or distance walked in the SMWT. Planning target volume size was significantly larger in the CRT arm, 142.79 cc (SD, 61.14), compared with the SBRT group, 46.15 cc (SD, 23.39). The mean biologically effective dose received by the target was significantly larger in the SBRT group, 125.92 Gy (SD, 21.58), compared with CRT, 65.49 Gy (SD, 6.32). Mean dose to the lungs minus the gross target volume incorporating motion was 8.9 Gy (SD, 2.34) in the CRT group and 4.37 Gy (SD, 1.42) in the SBRT group. CONCLUSIONS: Despite the considerably higher biologically effective doses delivered to the tumor in SBRT, there was no difference in decline in respiratory function observed between the 2 groups.
引用
- Bucknell NW, Kron T, Herschtal A, et al. Comparison of Changes in Pulmonary Function After Stereotactic Body Radiation Therapy Versus Conventional 3-Dimensional Conformal Radiation Therapy for Stage I and IIA Non-Small Cell Lung Cancer: An Analysis of the TROG 09.02 (CHISEL) Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 37087060. doi:10.1016/j.ijrobp.2023.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。